Genferon suppositories 1000000 ME 10 pcs
Condition: New product
977 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Interferon Alfa-2b + Taurine
Release form
Suppositories
Composition
In 1 suppositories: Interferon human recombinant alpha-2 1 mln.ME. Taurin 10 mg. Benzocaine 55 mg. Auxiliary substances: solid fat, dextran 60,000, polyethylene oxide 1500, tween-80, T2 emulsifier, sodium citrate, citric acid, water purified.
Pharmacological effect
Combined medication, the action of which is due to the components in its composition. It has a local and systemic immunomodulatory effects. Interferon alpha-2 has antiviral, antimicrobial and immunomodulatory effects. Under the influence of interferon alpha-2, the activity of natural killer cells, T-helper cells, phagocytes, as well as the intensity of B-lymphocyte differentiation, increases. Activation of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of primary pathological foci and restoration of production of secretory immunoglobulin A. Interferon alpha-2 also directly inhibits the replication and transcription of viruses, chlamydia. Taurin has membrane and hepatoprotective, antioxidant and anti-inflammatory properties, enhances tissue regeneration. Benzocaine is a local anesthetic. Reduces the permeability of cell membranes for sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, blocks the conduction of nerve impulses. It prevents the appearance of pain impulses in the endings of the sensory nerves and their passage through the nerve fibers.
Pharmacokinetics
When vaginal or rectal administration, interferon alpha-2 is absorbed through the mucous membrane, enters the surrounding tissues, into the lymphatic system, providing a systemic effect. Also, due to partial fixation on the cells of the mucous membrane, it has a local effect. Reducing the level of serum interferon 12 hours after the administration of the drug necessitates its repeated administration.
Indications
As part of complex therapy for infectious and inflammatory diseases of the urogenital tract: - genital herpes; - chlamydia; - ureaplasmosis; - mycoplasmosis; - recurrent vaginal candidiasis; - gardnerellez; - trichomoniasis; - papillomavirus infections; cervicitis; - vulvovaginitis; - bartholinitis; - adnexitis; - prostatitis; - urethritis; - balanitis; - balanoposthitis.
Contraindications
Hypersensitivity to the drug.
Use during pregnancy and lactation
If necessary, the use of the drug in the II and III trimesters of pregnancy should relate the expected benefits to the mother and the potential risk to the fetus.
Dosage and administration
In infectious and inflammatory diseases of the urogenital tract in women, the drug is administered intravaginally 1 supp. (250 thousand or 500 thousand IU, depending on the severity of the disease) 2 times / day for 10 days. In chronic diseases, the drug is prescribed 3 times a week (every other day) with 1 supp. within 1-3 months. In case of infectious and inflammatory diseases of the urogenital tract in men, the drug is prescribed rectally in 1 supp. (500 thousand-1 million IU, depending on the severity of the disease) 2 times / day for 10 days.
Side effects
Allergic reactions: skin rash, itching. These phenomena are reversible and disappear after 72 hours after reducing the dose or discontinuing the drug. When the drug is administered at a dose of 10 million IU / day, the risk of the development of the following side effects increases. : increased body temperature, increased sweating, fatigue, myalgia, loss of appetite, arthralgia.
Overdose
To date, cases of overdose Genferon drug have been reported.
Interaction with other drugs
When used together with antibiotics and other antimicrobial drugs used to treat urogenital infections, the effectiveness of Genferon increases. If used concurrently with vitamins E and C, the effect of interferon is enhanced. sulfonamides (due to the action of benzocaine).
special instructions
The drug should be used with caution in patients with allergic and autoimmune diseases in the acute stage.